Novo Nordisk A/S $NVO Stock Sold by Hikari Power Ltd

Hikari Power Ltd lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 80.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,300 shares of the company’s stock after selling 45,500 shares during the quarter. Novo Nordisk A/S accounts for about 0.1% of Hikari Power Ltd’s holdings, making the stock its 25th biggest holding. Hikari Power Ltd’s holdings in Novo Nordisk A/S were worth $428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in NVO. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Novo Nordisk A/S by 2,414.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after acquiring an additional 286,034 shares during the last quarter. Trust Co. of Vermont acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at approximately $1,250,000. Pine Valley Investments Ltd Liability Co acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at approximately $2,324,000. Myriad Asset Management Advisors LLC acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at approximately $1,846,000. Finally, The Manufacturers Life Insurance Company raised its position in Novo Nordisk A/S by 22.6% in the second quarter. The Manufacturers Life Insurance Company now owns 229,607 shares of the company’s stock valued at $11,007,000 after purchasing an additional 42,361 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NVO. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. UBS Group restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. DZ Bank reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, BMO Capital Markets set a $40.00 price objective on Novo Nordisk A/S and gave the company a “market perform” rating in a report on Monday, October 12th. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $59.44.

Novo Nordisk A/S Stock Down 0.8%

Shares of NYSE:NVO opened at $40.14 on Wednesday. The firm has a market capitalization of $179.23 billion, a PE ratio of 10.06, a price-to-earnings-growth ratio of 1.37 and a beta of 0.70. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. The firm’s 50-day moving average is $40.97 and its two-hundred day moving average is $44.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. Analysts predict that Novo Nordisk A/S will post 3.42 EPS for the current year.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo plans to repurchase 41.7 million shares under its $15 billion buyback program, which may support demand for the stock. Novo Nordisk stock and repurchases
• Positive Sentiment: New Wegovy and investigational CagriSema findings are expected at ObesityWeek, including real-world Wegovy results and additional CagriSema weight-loss outcomes. Strong data could bolster the obesity-drug pipeline and help restore confidence in future growth. Novo Nordisk obesity data
• Positive Sentiment: A valuation-focused article highlights NVO’s discount to sector peers, while another identifies the company as a potentially attractive dividend stock after a difficult year. These views may appeal to value-oriented investors, though they do not resolve near-term business risks. Novo Nordisk valuation Dividend-stock article
• Neutral Sentiment: Q3 results are a key upcoming catalyst. Investors are watching GLP-1 sales and management’s outlook; an article’s reference to substantial upside based on GF Value is a valuation estimate, not a forecast of earnings or share performance. Q3 results preview Earnings watch
• Negative Sentiment: Pre-earnings coverage flags intensifying GLP-1 competition, earnings estimate cuts and pricing pressure. Another report frames the November outlook around a trimmed target, while commentary points to a legal setback, Eli Lilly’s higher competitive bar and caveats around CagriSema. These concerns could weigh on growth expectations. Pre-earnings risks November challenges

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.